Publications by authors named "Bryan Kee"

Claim this Profile
H
Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial.
Ian W Folkert, Reza Mehran, Ryan Sun, Van K Morris, Michael J Overman, Bryan Kee

Ann Surg Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF metastatic colorectal cancer.
Van K Morris, Christine M Parseghian, Vahid Bahrambeigi, Nourhan Abdelfattah, Lianchun Xiao, Bryan K Kee

Cancer Cell· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.
Andrew J Pellatt, Alisha Bent, Nicholas Hornstein, Christine Parseghian, Ryan Huey, Bryan Kee

JCO Precis Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Landscape of ctDNA in Appendiceal Adenocarcinoma.
Michael G White, Mohammad A Zeineddine, Eleanor A Fallon, Fadl A Zeineddine, Julia Dansby, Bryan Kee

Clin Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy.
Vinay K Pattalachinti, Emaan Haque, Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Bryan Kee

NPJ Precis Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival.
Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Mohammad M Fanaeian, Mark Knafl, Bryan Kee

JAMA Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume.
Enoch Chang, Franklin C L Wong, Beth A Chasen, William D Erwin, Prajnan Das, Bryan K Kee

JNCI Cancer Spectr· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma.
Abdelrahman Yousef, Mahmoud Yousef, Mohammad A Zeineddine, Aditya More, Mohammad Fanaeian, Bryan Kee

JAMA Netw Open· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.
Kristen Simmons, Jane V Thomas, Kaysia Ludford, Jason A Willis, Victoria S Higbie, Bryan K Kee

Cancer Res Commun· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma.
Abdelrahman Yousef, Mahmoud Yousef, Mohammad Zeineddine, Aditya More, Saikat Chowdhury, Bryan Kee

medRxiv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing.
Stefania Napolitano, Aparna R Parikh, Jason Henry, Christine M Parseghian, Jason Willis, Bryan K Kee

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
Sarina A Piha-Paul, Chieh Tseng, Hai T Tran, Meng Gao, Daniel D Karp, Bryan K Kee

Cancer Chemother Pharmacol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Apostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson, Regina Mendrzyk, Amir Alpert, Bryan K Kee

Cancer Immunol Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival improvement for patients with metastatic colorectal cancer over twenty years.
Fadl A Zeineddine, Mohammad A Zeineddine, Abdelrahman Yousef, Yue Gu, Saikat Chowdhury, Bryan Kee

NPJ Precis Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer.
Jennifer S Davis, Janelle C Chavez, Melissa Kok, Yazmin San Miguel, Hwa Young Lee, Bryan Kee

JAMA Netw Open· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer.
Van K Morris, Michael J Overman, Michael Lam, Christine M Parseghian, Benny Johnson, Bryan K Kee

Cancer Res Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Benny Johnson, Cara L Haymaker, Edwin R Parra, Luisa Maren Solis Soto, Xuemei Wang, Bryan K Kee

J Immunother Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Colorectal cancer during pregnancy or postpartum: Case series and literature review.
Jane E Rogers, Terri L Woodard, Graciela Mn Gonzalez, Arvind Dasari, Benny Johnson, Bryan Kee

Obstet Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and pathologic features correlated with rare favorable survival in patients with mutated colorectal cancer.
Van Morris, Bryan Kee, Michael Overman, Arvind Dasari, Kanwal Raghav

J Gastrointest Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Clinical and Molecular Characterization of -Mutant Colorectal Cancer.
Jason T Henry, Oluwadara Coker, Saikat Chowdhury, John Paul Shen, Van K Morris, Bryan Kee

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience.
Jane E Rogers, Terri L Woodard, Arvind Dasari, Bryan Kee, Prajnan Das

Support Care Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer.
Shailesh M Advani, Michael D Swartz, Jonathan Loree, Jennifer S Davis, Amir Mehvarz Sarsashek, Bryan Kee

Clin Colorectal Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.
Preeti Kanikarla Marie, Cara Haymaker, Edwin Roger Parra, Young Uk Kim, Rossana Lazcano, Bryan Kee

Clin Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism.
Alexandre A Jácome, Aki Ohinata, Armeen Mahvash, Michael J Overman, Bryan Kee

Clin Colorectal Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer.
Benny Johnson, Jonathan M Loree, Alexandre A Jacome, Shehara Mendis, Muddassir Syed, Bryan Kee

JCO Precis Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis